San Diego, Calif. and Amsterdam, the Netherlands – Today at the American Thoracic Society (ATS) Conference 2018, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced new data suggesting that combining home oxygen therapy (HOT) with home non-invasive ventilation (HMV) as treatment for chronically hypercapnic COPD patients is more effective and less expensive than HOT alone. Comparing the accumulated costs of devices, doctor visits, medication, and hospitalizations to HOT alone using a US economic model, HOT-HMV exhibited an average annual cost savings of $3,927 per patient [1].
“Patients who suffer from COPD and face frequent hospitalization due to their disease previously had limited treatment and care options available to them,” said Dr. Nicholas Hart, professor and clinical director of Lane Fox Respiratory Service, St Thomas’ Hospital in London. “We’re all searching for healthcare solutions that improve patient outcomes, but are also economically feasible – and scalable. For that reason, it’s exciting to see data showing we can achieve both of these through a combination of therapies.”